

Beta Galactosidase (β -Gal) Inhibitor Screening Kit (Fluorometric)

6/15

(Catalog # K827-100; 100 assays; Store at -20°C)

I. Introduction:

Beta Galactosidase (β -Gal, EC: 3.2.1.23) is an enzyme which hydrolyzes the β -galactosides into monosaccharides. β -Gal is widely used as a reporter gene in the field of molecular biology. Senescence Associated β -Gal (SA- β -Gal) is an isoform of β -Gal which has the optimal activity at pH 6.0, and is mostly used as a biomarker for senescent cells (K802). β -Gal is an essential enzyme in humans and its deficiency results in Morquio's Syndrome, a severe birth defect. β -Gal can also be used as a tool to study protein-protein interaction. In BioVision's Beta-Galactosidase Inhibitor Screening Kit, β -Gal converts β -Gal substrate to give an intensely fluorescent product (Ex/Em = 480/520 nm). In the presence of a β -Gal inhibitor, the reaction is impeded/abolished resulting in decrease or total loss of fluorescence. This assay kit can be used to screen/study/characterize the potential inhibitors of Beta Galactosidase. The assay is simple, high-throughput adaptable and can be performed within 30 min.



II. Application:

- Screening/characterizing/studying potential inhibitors of Beta-Galactosidase.

III. Kit Contents:

Components	K827-100	Cap Color	Part Number
β -Gal Assay Buffer	25 ml	WM	K827-100-1
β -Gal Substrate (in DMSO)	200 μ l	Blue	K827-100-2
β -Galactosidase	1 vial	Purple	K827-100-3
β -Gal Inhibitor Control	1 vial	Orange	K827-100-4

IV. User Supplied Reagents and Equipment:

- 96-well white plate with flat bottom
- Multi-well spectrophotometer (fluorescent plate reader)

V. Storage Conditions and Reagent Preparation:

Store kit at -20°C, protected from light. Briefly centrifuge small vials prior to opening. Read entire protocol before performing the assay.

- β -Gal Assay Buffer:** Bring to room temperature before use. Store at -20°C or 4°C.
- β -Gal Substrate:** Thaw at room temperature. Aliquot and store at -20°C.
- β -Galactosidase:** Reconstitute with 550 μ l β -Gal Assay Buffer. Aliquot and store at -20°C. Avoid freeze/thaw. Keep on ice while in use. Use within two months.
- β -Gal Inhibitor Control:** Reconstitute with 200 μ l dH₂O. Aliquot and store at -20°C. Avoid freeze/thaw. Keep on ice while in use. Use within two months.

VI. β -Gal Inhibitor Screening Protocol:

1. Screen Compounds, Inhibitor Control, and Enzyme Control Preparation: Dissolve candidate inhibitors into an appropriate solvent at 100X the final concentration to be tested. Dilute to 2X desired test concentration with β -Gal Assay Buffer. Add 50 μ l diluted candidate inhibitor or β -Gal Assay Buffer into desired wells, as Sample [S], or Enzyme Control [EC] (no inhibitor). For Inhibitor Control (IC), dilute Inhibitor Control 5 times by adding 20 μ l Inhibitor Control to 80 μ l β -Gal Assay Buffer. Add 50 μ l of diluted Inhibitor Control into desired well(s).

Note: Solvents used to solubilize the inhibitors might affect the enzymatic activity. If solvent effect on enzymatic activity is a concern, prepare a solvent control well(s) with the same final concentration of the solvent(s) as in the inhibitor sample(s) as solvent controls (SC).

2. β -Gal Enzyme: Add 5 μ l β -Gal Enzyme into Sample, Enzyme Control, and Inhibitor Control wells (if necessary, in Solvent Control wells). Incubate for 5 min. at 25°C. Add 55 μ l of Assay Buffer into separate well designated as BC (Background Control).

3. Substrate Solution Preparation: Make enough reagents for the number of assays to be performed. For each well, prepare 45 μ l of Substrate solution containing:

β -Gal Assay Buffer	43 μ l
β -Gal Substrate	2 μ l

Mix and add 45 μ l of Substrate solution into each well. Mix well with gentle shaking, protected from light.

4. Measurement: Measure fluorescence (Ex/Em = 480/520 nm) in kinetic mode for 5-30 min. at 37°C. Choose two time points (T_1 & T_2) in the linear range of the plot and obtain the corresponding values for the fluorescence (RFU₁ & RFU₂).

5. Calculations: Subtract from all samples the background ($\Delta BC = BC_2 - BC_1$). Calculate the slope for all Samples (S), including Enzyme Control (EC), by dividing the corrected Δ RFU (RFU₂-RFU₁) values with the time ΔT ($T_2 - T_1$).

$$\% \text{ Relative Inhibitor} = \frac{(\text{Slope of EC} - \text{Slope of S})}{\text{Slope of EC}} \times 100$$

Notes:

- a. Irreversible inhibitors that inhibit the β -Gal activity completely at the tested concentration will have Δ RFU = 0 and thus the % Relative Inhibition will be 100%.
- b. In case Solvent Control(s) has substantially different slope(s) than the EC, use SC slope(s) instead of Slope of EC in the equation above.




Figure: Inhibition of Beta-Galactosidase activity by β -Gal Inhibitor (b-D-Galactopyranosyl Amine). $IC_{50} = 25.30 \mu$ M. Assay was performed following the kit protocol.

VII. Related Products:

Beta-Galactosidase Staining Kit (K802)
 Factor Xa Inhibitor Screening Kit (K362)
 Myeloperoxidase (MPO) Inhibitor Screening Kit (K746)
 pCAF Inhibitor Screening Assay (K345)
 HMG-CoA Reductase Activity/Inhibitor Screening kit (K588)
 SIRT2 Inhibitor Screening Assay Kit (K322)
 Beta-Galactosidase Activity Assay Kit (K821-100)

AHCY Inhibitor Screening Kit (K326)
 Human Calpain 1 Inhibitor Screening Kit (K244)
 p300 Inhibitor Screening Kit (K346)
 TACE Inhibitor Screening Assay Kit (K366)
 SIRT1 Inhibitor/Activator Screening Kit (K325)
 SIRT6 Inhibitor Screening Assay Kit (K323)

FOR RESEARCH USE ONLY! Not to be used on humans.